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Background: In sub-Saharan Africa, children with Plasmodium falciparum malaria and anaemia are often given iron
supplementation at the time of malaria treatment. Inflammation during and after malaria may decrease iron absorption,
thus, absorption might be improved if the start of supplementation is delayed. The study objective was to measure iron
absorption from iron supplements started immediately or delayed by two weeks after completion of therapy against
uncomplicated P. falciparum malaria.
Methods: Malawian toddlers (n = 48; age 12–24 months) were alternatively assigned to two groups according to their
appearance at the health centre: group A was provided iron supplements (30 mg Fe daily) as a FeSO4-containing syrup
for eight weeks starting immediately after malarial treatment; group B was given the iron after a two-week delay. Iron
absorption from the syrup was measured on the first day of iron supplementation, and after two and eight weeks in
both groups. Haemoglobin (Hb), iron status and inflammation were assessed every two weeks. Fractional iron
absorption at each time point and cumulative absorption was quantified by measuring erythrocyte incorporation
of 57Fe and compared using mixed models.
Results: Comparing group A and B, geometric mean iron absorption did not differ on the first day of supplementation
(9.0% vs. 11.4%, P = 0.213) and cumulative iron absorption from the three time points did not differ (6.0% vs. 7.2%,
P = 0.124). Hb concentration increased in both groups two weeks after malaria treatment (P < 0.001) and did not
differ after eight weeks of supplementation (P = 0.542).
Conclusions: In anaemic toddlers after uncomplicated malaria, a two-week delay in starting iron supplementation
did not significantly increase iron absorption or Hb concentration. Iron absorption is sufficiently high in the immediate
post-malaria period to warrant supplementation. These findings suggest there is no need to change the current practice
of immediate iron supplementation in this setting.
Trial registration: This trial was registered at Pan African Clinical Trials Registry (pactr.org) as PACTR2010050002141682.
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Anaemia affects more than 1.7 billion people worldwide
[1]. In low-income countries of sub-Saharan Africa,
major causes of anaemia are infectious diseases, particu-
larly malaria, and diets low in bioavailable iron [2,3].
Malarial anaemia is caused by a combination of red cell
lysis and inflammation. During malaria, high levels of
pro‐inflammatory cytokines increase serum hepcidin and
this limits the release of recycled red cell iron seques-
tered in macrophages and other reticuloendothelial cells
[4] and reduces dietary iron absorption [5,6]. Both
mechanisms decrease the amount of circulating iron
resulting in impaired erythropoiesis and the anaemia of
inflammation [7]. Therefore, in a child presenting with
malaria and anaemia, the anaemia may be due to red
cell lysis, nutritional iron deficiency and inflammation
caused by the infection.
The prevalence of iron deficiency among Malawian
pre-school age children in the rural region is high, about
75%, and similar rates are reported from other African
countries [8]. In sub-Saharan Africa, a child with malaria
and anaemia is often given anti-malarial treatment and
iron supplementation [9], and the iron supplements are
usually started directly after the malarial treatment, in
order to reduce clinic visits and increase compliance. Al-
though there are concerns that iron supplements may
increase the intensity of a Plasmodium infection [10],
they are recommended for anaemic children in areas of
adequate malarial surveillance and health care [9]. How-
ever, the efficacy of providing iron immediately after
malarial treatment has been questioned. Doherty et al.
supplemented young Gambian children aged 18 to
36 months with daily 2 mg/kg elemental iron (as iron
glycine sulphate) directly after treatment of acute un-
complicated malaria. Using stable iron isotopes, they
found that iron absorption was 8% when given directly
after the treatment and was 15% after 2 weeks; the au-
thors hypothesized this was due to lower inflammation
at the later time point [5]. Afebrile (asymptomatic)
Plasmodium falciparum malaria causes inflammation
which decreases iron absorption in Beninese women
by 40% [6] and in Ivorian children by 100% (Glinz et al.,
personal communication). These and the findings from
Doherty suggest that iron absorption within the first two
weeks after treatment of acute malaria is not sufficient to
warrant iron supplementation in this period. Hence, iron
supplements begun two weeks after treatment of acute
malaria might be twice as well absorbed than those given
immediately after treatment.
Therefore, the objective of the present study was to
measure iron absorption from iron supplements at three
subsequent time points in toddlers with acute uncom-
plicated malaria, who were treated against malaria and
had begun iron supplementation either immediately aftertreatment (group A) or after a delay of two weeks
(group B). In the group A, iron absorption was mea-
sured at 0, 2 and 8 weeks after anti-malarial treatment,
and in group B, at 2, 4 and 10 weeks after anti-malarial
treatment. The hypothesis of the present study was that
cumulative iron absorption at the three time points
would be greater in group B than in group A.
Methods
Study site and study population
The study was conducted in southern Malawi at the
Zomba Central Hospital in Zomba, Malawi. The study
was initiated in January 2012 and was completed in
September 2013. The present study joined forces with a
larger randomized controlled trial, which is assessing ad-
verse events of iron supplementation in children after
anti-malarial treatment and is aiming to assign 600 chil-
dren. The present study was conducted in parallel of this
study, i.e. children were either assigned to the larger
trial or to the present study, but benefitted from the in-
frastructure (trained technicians, nurses, etc.). Malaria
transmission is moderate-to-intense perennial with a
seasonal peak, i.e. large rainy season from November to
March. A sample size of 18 children in each group was
calculated to be sufficient to detect a 40% difference in
iron absorption between study groups, based on a stand-
ard deviation of 0.228 in (log-transformed) iron absorp-
tion from previous studies at the ETH Zurich [6,11,12],
and 80% power and a type I error rate of 5%. Anticipat-
ing a 10% drop-out rate, 20 children in each study
groups was deemed to be satisfactory.
Toddlers were recruited at Zomba Central Hospital
if they met the following inclusion criteria: i) aged
12–24 months; ii) body weight 8–12 kg; iii) moderate
anaemia defined as Hb concentration between 70–100 g/L;
iv) documented uncomplicated malaria and completed
treatment with artemether-lumefantrine dispersible
(LA), [artemisinin (20 mg) and lumefantrine (120 mg),
Novartis, Basel, Switzerland, per day, over three consecu-
tive days]; v) history of fever within the last 48 hours;
vi) no known adverse reactions to oral iron; vii) HIV
sero-negative; viii) absence of major systemic illnesses;
ix) anticipated residence in the study area for the entire
study duration; x) no iron supplementation in the month
preceding enrolment; xi) written informed consent from
a parent/guardian to participate in the study. Docu-
mented uncomplicated malaria was referred to when it
was documented in the health passport or other hospital
notes on the out-patient department for a child who
presented to the hospital with a) history of fever in the
previous 24 hours or was febrile on the examination
with or without other symptoms of malaria like general
body pains; and b) was positive for P. falciparum by
microscopic examination of the blood smear. All signs
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respiratory distress or altered consciousness were ex-
cluded for on examination [13]. In sequence, toddlers
fulfilling these criteria were alternately assigned into the
two groups. Reasons for discontinuation of the study
were: i) problems with the administration of the stable
iron isotope, ii) repeated difficulties with the blood taking,
iii) any infection or injuries leading to hospitalization, or
iv) recurrent P. falciparum infection that became febrile. If
a child dropped out of the study, another child was re-
cruited into that group to reach a number of 20 children
completing the study in each group (i.e. 19 children in
group A completed visit 6 and 20 children in group B
completed visit 7).
Study procedures
The study started on the first day (visit 1) after com-
pletion of the anti-malarial treatment with LA. All
children received daily iron supplementation of 30 mg
iron (assuming an average body weight of 10 kg) for a
period of eight weeks. During this period, a total of three
iron absorption studies in each group was conducted.
Children’s full medical history was recorded, the children
were examined on the day of recruitment (visit 1) and
demographic information were collected including a de-
tailed location map of their residence. Participants in
study group A started with iron supplementation on the
first day after completion of malarial treatment (visit 1).
In group A, the time points for iron absorption studies
were at the first day after anti-malarial treatment comple-
tion (visit 1), after 2 weeks (visit 2) and after 8 weeks
(visit 5) (Figure 1). Participants in study group B started
with iron supplementation two weeks after they had
completed their malarial treatment. The time points for
the iron absorption studies in group B were at 2 weeks
(visit 2), 4 weeks (visit 3) and 10 weeks (visit 6) after the
completion of malarial treatment (Figure 1). Each mother
was asked to come for a scheduled follow-up visit at
the research unit at the Zomba Central Hospital every
other week.
Iron supplementation and iron isotope preparation
and administration
Children received iron sulfate (30 mg Fe daily, assuming
a mean body weight of 10 kg) as syrup (Enfamil®
Fer-In-Sol®, Mead Johnson & Company, USA) for eight
weeks, except on the three days of the stable iron isotope
studies. The mothers were trained in the iron supple-
mentation administration and the handling of the dispen-
ser. Mothers administered the iron directly into the
mouth of the child from a dropper. The bottles contain-
ing iron syrup were weighted before bottles were handed
out to the mothers and weights were recorded in a log-
file. Mothers were asked to bring back the bottles foreach visit, when the bottles were weighted to ascertain
compliance and if needed mothers were advised with re-
spect to correct administration.
The stable iron isotope (elemental 57Fe, 97.82% isotopic
enrichment) were obtained from Chemgas, Boulogne,
France. 57FeSO4 was prepared from isotopic enriched
57Fe
by dissolution in 0.1 mol H2SO4/L. On the day of stable
isotope administration, children received an oral dose of
27 mg unlabelled Fe and 3 mg 57Fe (both as FeSO4
in solution) in the morning after at least a two-hour
supervised fast. The acidified solution (FeSO4) was sweet-
ened by adding 0.5 ml orange squash (Sobo orange syrup,
Southern Bottlers, Blantyre Malawi). The solution was
kept refrigerated (5°C) in plastic containers. The same
study nurse performed the isotope administration with
a disposable dropper (plastic Pasteur pipette) for all
participants and the local investigator supervised the
administration procedure. The plastic container with iron
isotope and dropper were rinsed twice with 2 ml water-
orange squash mix (1:1). All children were observed for
three hours after iron isotope administration and any
spillage or vomiting was recorded. The protocol of iron
isotope administration was repeated after two and eight
weeks. In between the time points of isotope administra-
tion, children continued with normal iron supplemen-
tation of 30 mg/day for a total of 8 weeks. Group A
finished the supplementation 8 weeks after malarial
treatment and the last blood sample was drawn after
10 weeks. Group B finished the supplementation with
a two-week delay, i.e. at week 10, and the last blood
sample was drawn 12 weeks (visit 7) after treatment.
Blood analysis
Venous blood samples (3 ml) were collected in EDTA-
coated tubes (Becton Dickinson AG, Allschwil, Switzerland)
on the day of iron isotope administration (before the
administration) and every other week. For group A,
the first full blood sample was collected at visit 1 and
the last at visit 6. For group B, the first full blood
sample was collected at visit 2 and the last at visit 7
(Figure 1). When insufficient blood was obtained from
a venepuncture for all analyses, isotopic analyses were
prioritized.
The HIV status of the child was examined at recruitment
with Determine HIV Test (Alere GmbH, Switzerland). Hb
concentration was measured with a HemoCue® Hb 201+
(HemoCue AB, Angelholm, Sweden) on the screening day.
Subsequently, full blood count was performed with an au-
tomated haematology analyzer Sysmex KX-21 N (Sysmex,
USA). One ml full blood was frozen at −20°C for iron
isotope quantification. Plasma was separated and fro-
zen at −20°C under temperature controlled condition
avoiding freeze-thaw cycles. Frozen full blood and plasma
samples were transferred to Switzerland and Germany.
Figure 1 Study flowchart. Overview of the study design of the stable iron isotope absorption studies conduction in Malawian toddlers aged 12
to 24 months.
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and plasma ferritin (PF) concentrations were analysed in
Germany with a sandwich enzyme-linked immunosorbentassay described elsewhere [14]. Although it was planned
to measure soluble transferrin receptor, for technical
reasons it was not possible to accurately measure it in
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EDTA in the collection tubes (Jürgen Erhardt, personal
communication, 2014).
Isotope enrichment was quantified in the Laboratory
of Human Nutrition at ETH Zürich, Switzerland. The
enriched whole blood samples were mineralised by
microwave digestion and iron was separated by anion-
exchange chromatography and a subsequent solvent-
solvent extraction step into diethylether [15]. Iron was
analysed by negative thermal ionization mass spec-
trometry (TIMS) with a magnetic sector field mass
spectrometer (Finnigan MAT 262; Thermo Finnigan,
Bremen, Germany) equipped with a multicollector system
for simultaneous ion beam detection. The calculation of
amount of 57Fe label present in the blood was based on
isotope-dilution [15]. Circulating iron was calculated from
the blood volume based on height, weight and Hb concen-
tration [16], assuming that the blood volume in children
after malarial treatment is not different from healthy chil-
dren. One hundred percent incorporation of the absorbed
iron into red blood cells was assumed for calculation of
fractional absorption [17]. The blood collected before each
label administration was used as the isotopic enrichment
baseline for the subsequent absorption calculation. The
cumulative iron absorption was calculated based on the
sum of the three oral doses, the isotopic enrichment mea-
sured in the very last collected blood sample, and the very
first isotopic enrichment baseline sample. Because the
calculations of the fractional iron absorption and the cal-
culations of cumulative iron absorption are different, the
number of quantified iron absorptions at the last time
point and the number of quantified cumulative iron ab-
sorptions might be different.
Thick blood smears for P. falciparum asexual para-
sites were prepared and examined. A thick smear
was considered as negative if 100 microscopic fields
revealed no parasites. Thick blood films were stained
with Giemsa and were microscopically examined for
Plasmodium species parasitaemia. Malaria parasites
were counted against 200 leucocytes. Counts were
converted to number of parasites/μL blood assuming
8,000 leucocytes/μL blood [18].
Ethics
The ethics committees of ETH Zürich (reference no.
EK 2011-N-54) and College of Medicine, Blantyre
(COMREC P.01/10/859) approved the study. The trial
was registered at pactr.org (PACTR2010050002141682).
Health authorities and parents/guardians of the partici-
pating children were informed about the purpose, proce-
dures, and potential risks and benefits of the study.
Written informed consent was obtained from parents/
guardians of the participating children. Participation was
voluntary; hence one could withdraw from the study atany time without further obligations. Participants re-
ceived no remuneration for participation, but travel costs
for scheduled and sick visits were paid by the study.
Statistics
Data was double entered in Microsoft Access 2010
(2010 Microsoft Corporation) and verified by a data offi-
cer against original clinical records. Data was analysed
with STATA version 11.1 (StataCorp LP; USA). All chil-
dren were included into the final analysis who had an
iron absorption measurement from first stable iron iso-
tope study (completion of visit 2 in group A and com-
pletion of visit 3 in group B), even if they subsequently
missed follow-up visits. Iron absorption, iron status and
inflammation parameters were assessed with linear regres-
sion mixed (random and fixed effects) models. When
modelling, both time (visits) and group were considered
as categorical and the random effects allowed to vary
within participants (child-level). For each time point, the
residuals of all parameters were assessed for normality
with Q-Q and box plots. If residuals were not normally
distributed, data were log-transformed. All models were
assessed for time effects within groups and interaction of
study groups and time. The geometric mean iron absorp-
tion of all isotope doses (total isotopic enrichment) in the
last collected blood sample was compared between both
groups with a simple t-test for unpaired data, after the in-
dividual data was log transformed.
Results
Subjects
Forty-eight children completed the first iron absorption
study (24 each in group A and B) and were considered
for statistical analysis with mixed models. Twenty-three
children dropped out during the study (Figure 1).
Twenty (87%) of the drop-outs occurred within the first
four weeks (i.e. up to the third visit).
The mean (±SD) age at visit 1 was 19.0 ± 3.9 months in
group A and 16.7 ± 3.8 months in group B. Fifty percent of
the children in group A and 58% in group B were boys.
Mean (±SD) body weight at baseline was 10.2 ± 1.0 kg in
group A and 9.8 ± 1.0 kg in group B. Of the children in
group A, 21, 15, and 14 subjects completed the first, sec-
ond and third iron absorption studies respectively. In
group B, 20, 16 and 16 subjects completed the first, second
and third iron absorption studies respectively. Seventeen
children in group A and 16 children in group B received
the iron isotopes at all 3 time points and provided the final
blood sample, and for these the cumulative isotopic enrich-
ment over the eight-week study was calculated.
Treatment of malaria and reinfection
All toddlers had no malaria parasites on the day after com-
pleting malarial treatment. Re-infection was common: at
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groups was re-infected; at visit 3 (four weeks), one
child in group B was re-infected; at visit 4 (six weeks)
one child in group A and three in group B were re-
infected; at visit 5 (eight weeks), one child in group A was
re-infected; at visit 6 (10 weeks) no child was re-infected
and at visit 7 (12 weeks) two children in group B were re-
infected.
Iron absorption
Geometric mean fractional iron absorptions at visit 1,
visit 2 (two weeks) and visit 5 (eight weeks) in group A
were 9.0% (95% CI: 7.4 – 11.0%), 8.8% (95% CI: 6.5 –
11.8%) and 3.1% (95% CI: 2.1 – 4.7%) (Figure 2). In
group B, geometric mean iron absorptions at visit 2 (two
weeks), visit 3 (four weeks) and visit 6 (10 weeks) were
11.5% (95% CI: 10.0 – 13.1%), 5.7% (95% CI: 3.9 – 8.5%)
and 3.9% (95% CI: 2.4 – 6.4%). Fractional iron absorp-
tion was not significantly different (P = 0.213) between
group A (visit 1) and group B (visit 2). Mean fractional
iron absorption was also not significantly different be-
tween the groups at two weeks (P = 0.052) and eight
weeks (P = 0.311) The geometric mean fractional iron
absorption (measured by cumulative isotopic enrichment)
from the three isotope doses over the eight-week period
was 6.0% (95% CI: 5.1 – 7.1%) in group A and 7.2%
(95% CI: 6.1 – 8.4%) in group B, and was not signifi-
cantly different (P = 0.124). Iron absorption in group
A did not change between visit 1 and visit 2, but de-
creased significantly from 8.8% at visit 2 to 3.1% at
visit 5 (P = 0.002). Iron absorption in group B decreasedFigure 2 Box plots of iron absorption after uncomplicated malaria. Bo
supplementation measured in Malawian toddlers assigned to group A (n =
and 75th percentiles, lower and upper limits, and dots represent outliers. Ad
group A started the 8-week iron supplementation immediately after malari
and 8. Toddlers in group B started the 8-week iron supplementation with a
Abbreviations: Fe, iron. a,b,c,dWithin and between group comparison: different le
values within one parameter carry the same superscript letter, they are not signsignificantly from 11.8% at visit 2 to 5.9% at visit 3
(P = 0.001), but did not differ between visit 3 and visit 6.
Inflammation and iron indices
In group A, median CRP and AGP concentrations were
elevated directly after completion of malarial treatment
(Table 1); two weeks later, the inflammation had resolved.
No blood samples from group B at visit 1 were collected;
the first venous blood sample in group B was collected
at visit 2, i.e. two weeks after anti-malarial treatment
completion, and inflammation status was not different
from group A at visit 2. From two weeks onward, in-
flammation markers remained normal in both groups.
Median plasma ferritin (PF) was high directly after mal-
arial treatment in group A and significantly decreased
from 189 μg/mL to 57 μg/mL (P < 0.001) two weeks later
(visit 2) (Table 1). The PF concentration at baseline in
Group A was significantly increased compared to the
other time points within group A. In the following visits,
PF concentration was not different within each group and
between the two study groups, except at visit 2 when the
PF concentration in group B was significantly lower and at
visit 7 in group B when PF concentration increased to
102 μg/mL. At visit 1, mean Hb concentration was 84 g/L
in group A and 80 g/L in group B. Mean Hb concentra-
tion increased significantly (within group) in both groups
A and B two weeks after treatment (at visit 2) to 104 g/L
(P < 0.001) and 100 g/L (P < 0.001) respectively, and in-
creased further to 114 g/L in both groups during the
course of the treatment without statistical difference be-
tween the two groups (Figure 3).x plots of fractional iron absorption at three time points during iron
24) and group B (n = 24). Each boxplot represents the medians, 25th
ditionally, the geometric mean was added as dashed line. Toddlers in
al treatment and the iron absorption was quantified at week 0, 2
2-week delay and iron absorption was measured at week 2, 4 and 10.
tters indicate statistical significance (P < 0.05), i.e. if two mean/median
ificantly different, i.e. P > 0.05.
Table 1 Iron absorption, iron and inflammation parameters among Malawian toddlers after anti-malarial treatment
1. visit 2. visit 3. visit 4. visit 5. visit 6. visit 7. visit
0 weeks 2 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks
Absorption (geometric mean%, 95% CI)
A 9.0a (7.4-11.0) 8.8a,c (6.5-11.8) N.A. N.A. 3.1b (2.1-4.7) N.A. N.A.
B N.A. 11.5a (10.0-13.1) 5.7c,d (3.9-8.5) N.A. N.A. 3.9b,d (2.4-6.4) N.A.
Haemoglobin concentration (g/L, mean, ±SD)
A 84a ± 7 104b ± 9 113d ± 10 116d ± 9 111c,d ± 12 114d ± 13 N.A.
B* 80a ± 9 100b ± 9 106c ± 12 108c ± 11 109c,d ± 13 114d ± 14 111c,d ± 12
Plasma ferritin (μg/L, median, 25th 75th)
A 189a (142–263) 57b,c,d (36–94) 56b,c,d (38–84) 49b,c,d (40–90) 49b,c (34–64) 45b,c (30–69) N.A.
B N.A. 39c (14–52) 46c,b (28–102) 57b,d (34–88) 66b,d (37–99) 77b,d (45–169) 102d (56–163)
C-reactive protein (mg/L, median, 25th 75th)
A 36.7a (24.2-44.8) 1.6b (0.5-3.3) 3.6b (0.5-10.3) 1.6b (0.8-5.1) 2.1b (0.8-9.1) 1.4b (0.7-5.0) N.A.
B N.A. 2.5b (1.3-7.3) 2.2b (0.6-4.4) 4.3b (1.8-10.9) 3.3b (0.8-7.9) 1.1b (0.6-5.9) 4.3b (2.9-8.5)
AGP (g/L, median, 25th 75th)
A 1.86a (1.56-1.98) 1.05b (0.88-1.52) 0.98b (0.88-1.27) 1.07b (0.69-1.23) 1.09b (0.83-1.38) 1.02b (0.66-1.25) N.A.
B N.A. 1.25b (0.96-1.55) 1.06b,c (0.70-1.37) 1.07b,c(0.84-1.6) 1.01b,c (0.80-1.37) 0.86c (0.69-1.14) 1.10b,c (0.89-1.33)
Malawian toddlers presenting with post-malarial anaemia were supplemented with 30 mg iron for 8 weeks, either directly after malaria treatment (group A, n = 24) or
starting with a 2-week delay (group B, n = 24). Children received a dose of a stable iron isotope (57Fe) at three occasions, i.e. group A at week 0, 2 and 8 and group B at
week 2, 4 and 10. Iron and inflammation parameters are stratified by iron supplementation group and visits. Abbreviations: AGP, α1-acid glycoprotein; CI, confidence
interval; N.A., not applicable; SD, standard deviation.
a,b,c,dIf two mean/median values within one parameter carry the same superscript letter, they are not significantly different, i.e. P > 0.05. Different letters indicate
significant differences (P < 0.05) within and between groups A and B for iron absorption, iron and inflammation parameters were assessed with random
effect models.
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Figure 3 Recovery of haemoglobin concentration after uncomplicated malaria. Haemoglobin (Hb) concentration (±standard deviation (SD)
indicated by vertical bars) in Malawian toddlers (aged 12 to 24 months) with post-malarial anaemia starting 8-week iron supplementation either
directly after malarial treatment at week 0 (black) or starting delayed at week 2 (blue). a,b,c,dDifferent letters indicate significant (P = 0.05) differences
between and within groups, i.e. if two mean/median values within one parameter carry the same superscript letter, they are not significantly
different, i.e. P > 0.05.
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The main findings of this study are: a) toddlers receiving
iron supplementation with a two weeks delay did not
absorb significantly more iron over the eight week sup-
plementation period than the group starting supplemen-
tation immediately after treatment; b) in post-malarial
anaemia, the first dose of iron supplementation is not
better absorbed when given two weeks after malaria
treatment than directly after treatment; and c) Hb con-
centration increased during the first two weeks after mal-
aria treatment, with and without iron supplementation.
The present study did not confirm the findings of
Doherty et al. in children with acute malaria that iron
absorption increased by some 75% (from 8% to 14%)
two weeks after malarial treatment compared to iron
absorption immediately after malaria treatment [5]. Frac-
tional iron absorption in our children in group A imme-
diately after malarial treatment and two weeks later was
similar, although the absorption at visit 1 in the group A
receiving supplements immediately was 27% lower than
in group B (P = 0.213) receiving supplements after a
2 week delay at visit 2. One possible explanation for the
different outcomes in the Gambian study and our study
is that the 18–36 month old Gambian children received
3.9 mg 57Fe as isotopically labelled ferrous sulphate in
orange juice on the day after the malarial treatment but
a lower amount of iron (1.3 mg 58Fe) at the second ab-
sorption study 2 weeks later [5]. Fractional iron absorp-
tion is influenced by the amount of iron administered
[19] and is lower with higher amounts of iron. Addition-
ally, the Gambian children were administered isotopes
with orange juice, which would be expected to contain
ascorbic acid which increases iron absorption [20] and
might have a stronger influence on iron absorption
in Gambian children without infection than those with
infection.
However, other studies support the observations of
Doherty et al. from the Gambia. These include studies
from Benin which reported that iron absorption from an
iron fortified sorghum porridge by Beninese women with
malarial parasitaemia increased after malarial treatment
[6] and our studies in Ivorian children with malarial
parasitaemia (Glinz et al., personal communication)
which found that iron absorption from an iron supple-
ment was increased by 40%-100% two weeks after malar-
ial treatment. In both studies, inflammation parameters
were increased during afebrile malaria but normalized
two weeks after malarial treatment [6].
Immediately after malarial treatment, the inflamma-
tion indicators CRP and AGP in group A were elevated,
but they decreased significantly within 2 weeks to a level
which then remained constant over the following weeks.
This plateau level in group A was similar to the level in
group B, which also remained relatively constant overthe supplementation period. However, although inflam-
mation biomarkers decreased in group A, as discussed
above, fractional iron absorption did not increase over
this two week period. This might be explained by a
lag-time in the response of hepcidin compared to the
inflammation biomarkers, or be related to the daily
supplementation of 30 mg iron and improved iron sta-
tus leading to a lower iron absorption. Iron absorption
in group B decreased significantly over the first 2 weeks
of iron supplementation.
The results of the present study suggest that a fairly
high percentage of iron (9.0%) was absorbed when the
supplements were given immediately after anti-malarial
treatment. This amount of absorbed iron is likely to be
important to an anaemic child during early recovery
from malarial anaemia. This finding supports the current
practice of immediate iron supplementation of anaemic
or iron deficient children.
Based on the Hb concentration at the end of supple-
mentation, there appears to be no advantage of delaying
supplementation by two weeks. Hb concentration in-
creased within two weeks of malarial treatment irre-
spective of whether the child received iron supplements
or not. This is similar to the Gambian study [5] where
Hb concentration after malarial treatment in the an-
aemic children increased at a faster rate than in anaemic
children with iron deficiency but without precedent mal-
aria episode. This suggests that erythropoiesis was sup-
pressed due to malaria and recycled red cell iron was
trapped in the reticuloendothelial macrophages [7,21]. In
addition to impaired erythropoiesis due to the lack of
iron, it is also possible that erythropoiesis was impaired
by pro- and anti-inflammatory factors [22-24] or by the
malaria pigment haemozoin [25], that are increased dur-
ing malarial infection. After malarial treatment, it ap-
pears that normal erythropoietic activity is re-established
by mobilization of sequestered iron from macrophages
in the reticuloendothelial system [5]. Because recycled
red cell iron provides >90% of the iron for erythopoeisis,
while only 5-10% comes from absorbed dietary iron, iron
release from the macrophages after the malarial treat-
ment was probably responsible for the rapid increase in
Hb concentration in both groups. The findings of the
present study are in contrast to an earlier study among
Malawian children which reported that Hb concentra-
tion increased significantly after anti-malarial treatment
in children receiving iron supplements during four weeks
compared to children receiving no iron [26]. However,
these studies have a limited comparability, because group
B in our study was not a control group.
The present study has several limitations. It was aimed
to complete the study with approximately 20 children in
each study group. Because of a drop-out of n = 14 (42%)
in group A and n = 9 (31%) in group B it cannot be ruled
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the reasons for drop-out were diverse and similar in
both groups and probably did not create a risk of bias.
Moreover, the inclusion criteria were narrow and further
reduced the risk of bias. Another study limitation is the
alternate assignment to study group A and B, which is
not considered as proper randomization method and
hence, alternate assignment harbours the risk of potential
imbalances between group A and B at recruitment.
Moreover, no venous blood samples were collected from
group B at the first visit, thus potential imbalances be-
tween group A and B cannot be assessed. A further study
limitation might be the diminished iron absorption due
to recurrent P. falciparum infection, which remained
asymptomatic, i.e. 12% in group A and 14% in group B.
However, as asymptomatic recurrent infections occurred
to a similar extent in both groups, iron absorption was
probably influenced in a similar way, although the recur-
rent infections might have reduced the contrast between
both groups.
The present study did not address the potential safety
concerns of iron supplementation in young children in
sub-Saharan Africa. Iron may increase the intensity of
malarial infections and other infectious diseases [27,28].
Also, unabsorbed iron may increase the pathogenicity of
the gut microbiota [29], and the incidence of diarrhoea
[30,31]. WHO recommends supplementation when it is
accompanied by malarial surveillance and good health
care [9]. The participating children had no longer a de-
tectable P. falciparum infection after the full course of
treatment with LA and were free of malaria when sup-
plementation started. However, the half-life of artemisi-
nin is only 2–3 hours, and the half-life for lumefantrine
is about 3–4 days [32]. These short half-lives provide
protection against re-infection for only two to three
weeks [33]. As the study period was eight weeks, there
was an issue of safety [9], so the children were continu-
ously monitored throughout the eight weeks supplemen-
tation period, plus two weeks after completion of iron
supplementation, and did detect and treat reinfection.
Hence, close medical supervision was provided after the
protective effect of anti-malarial therapy had faded. Chil-
dren with asymptomatic parasitaemia were continued in
the study, but children with malaria (i.e. febrile P. falcip-
arum infection) were withdrawn. The risks of iron sup-
plementation after anti-malarial treatment were not
assessed in the present study. This issue is being evalu-
ated in our larger ongoing, randomized control trial,
which is assessing the safety of iron supplementation
after malarial treatment among 600 children. The
strengths of our present study are the longitudinal de-
sign, repeated measurement of iron absorption using
stable isotopes, and the biweekly follow-up in Malawian
toddlers.Conclusion
In conclusion, in anaemic toddlers after uncomplicated
malaria, a two-week delay in starting iron supplementa-
tion had no measurable benefit on iron absorption or on
the recovery of Hb concentration. The findings of the
present study show that iron absorption is sufficiently
high immediately after anti-malarial treatment and hence,
these findings suggest that there is no need to change
the current practice of immediate iron supplementation,
considering that compliance from supplementation given
immediately after malaria treatment is generally thought
to be higher in this setting.
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